Using whole exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities.

Abstract

Chemotherapies are associated with significant inter-individual variability in therapeutic effect and adverse drug reactions. In lung cancer, the use of gemcitabine and carboplatin induces grade 3 or 4 myelosuppression in about a quarter of the patients, while an equal fraction of patients are basically unaffected in terms of myelosuppressive side effects. We therefore set out to identify genetic markers for gemcitabine/carboplatin-induced myelosuppression.